Drugs · acquisition-cost intelligence
Enalapril Maleate
Enalapril· ingredient enalapril· ENALAPRIL MALEATE 1 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.95754
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other enalapril products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Vasotec | $0.07125 | −$0.88630 |
| Enalapril maleate | $0.07354 | −$0.88400 |
| Enalapril maleate and hydrochlorothiazide | $0.18496 | −$0.77260 |
Medicare Part D coverage · CY2026
On 8 plan formularies · typical tier 1
Prior auth 0% · Step therapy 88% · Quantity limit 88% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.